WebJan 11, 2024 · 2024 Investor Day Presentation . Jun 29, 2024. Bio-Techne to Acquire Exosome Diagnostics . Sep 15, 2016. 2016 Investor Day Presentation . Email Alerts; … Business Description. Bio-Techne Corporation (NASDAQ: TECH) is a … Learn about our life science & clinical diagnostic brands including R&D … Latest Presentation. January 11, 2024. Corporate Presentation - January 2024 … Press Releases - Presentations :: Bio-Techne Corporation (TECH) Annual Reports - Presentations :: Bio-Techne Corporation (TECH) Financial Results - Presentations :: Bio-Techne Corporation (TECH) IR Calendar - Presentations :: Bio-Techne Corporation (TECH) All SEC Filings - Presentations :: Bio-Techne Corporation (TECH) Financial Information - Presentations :: Bio-Techne Corporation (TECH) Stock Data - Presentations :: Bio-Techne Corporation (TECH) WebBio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following ...
Presentations Charles River Laboratories International, Inc.
WebCertain of the statements made in this presentation are forward looking, such as those, among others, relating to the Company’s 2024 outlook, including anticipated revenues, costs and expenses, and its potential for growth; the Company’s potential to achieve the noted development and regulatory milestones in 2024 and in future periods, if at all; … WebJan 16, 2024 · Bio-Techne Corporation (TECH) Investor Presentation - Slideshow. Jan. 16, 2024 1:17 PM ET Bio-Techne Corporation (TECH) SA Transcripts. 135.46K Followers. Follow. deter rabbits from hostas
BIO-TECHNE TO SHOWCASE INNOVATIVE CANCER RESEARCH, …
Web1 day ago · MINNEAPOLIS, April 13, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will present its portfolio of products and solutions to advance cancer research and enable cell... WebMar 31, 2024 · As of March 31, 2024, BIO-TECHNE Corp had a $11.4 billion market capitalization, putting it in the 89th percentile of companies in the Biotechnology & Medical Research industry. Currently, BIO-TECHNE Corp’s price-earnings ratio is 46.2. BIO-TECHNE Corp’s trailing 12-month revenue is $1.1 billion with a 23.4% profit margin. WebAug 22, 2014 · Bio-Techne @biotechne · Feb 15 Just 1 month to go until our #SCOPE2024 User Meeting in the Netherlands. Join us to advance your spatial gene expression research, through keynote presentations, workshops, and networking. Register here: bit.ly/3R7szL7 Bio-Techne @biotechne · Feb 14 churba deco lighting